Skip to main content
. 2020 Nov 25;6(4):239–250. doi: 10.1007/s40675-020-00195-7

Table 3.

Meta-review of narcolepsy: prevalence rates (95% CI)

Diverse population Children Adults Child-adult age range All ages combined Diverse population Children Adults Child-adult age range All ages combined
A. Before the H1N1 pandemic B. During/after the H1N1 pandemic in unvaccinated populations
Europe

11.07

(2.96–19.18)

2.46

(2.16–2.76)

0.09

(0–0.23)

2.92

(2.64–3.19)

 Europe

3.36

(2.55–4.18)

7.42

(5.51–9.33)

17.58

(13.5–21.67)

5.69

(4.87–6.51)
k = 5; I2: 98.78 k = 11; I2: 99.71 k = 3; I2: 88.42 k = 19; I2: 99.68 k = 11; I2: 98.86 k = 12; I2: 99.32 k = 1; I2: 0 k = 24; I2: 94.05
North America

6.63

(5.03–8.23)

2.59

(0.10–5.79)

26.03

(17.29–34.77)

5.14

(2.40–7.87)

 North America

6.91

(3.51–10.31)

7.56

(6.55–8.57)

 -

7.53

(6.64–8.43)
k = 1; I2: 0 k = 4; I2: 98.79 k = 1; I2: 0 k = 6; I2: 98.51 k = 2; I2: 57.79 k = 2; I2: 0 - k = 4; I2: 0
Asia

4.53

(3.02–6.04)

6.93

(5.06–8.80)

0.35

(0.02–0.68)

3.57

(3.09–4.06)

 Asia

7.74

(0.97–14.52)

9.09

(4.99–13.20)

16.76

(11.21–2.32)

8.22

(5.97–10.48)
k = 4; I2: 99.38 k = 5; I2: 99.85 k = 3; I2: 95.86 k = 12; I2: 99.68 k = 2; I2: 97.67 k = 4; I2: 99.07 k = 1; I2: 0 k = 8; I2: 98.53
Caucasian

10.19

(3.35–17.04)

3.84

(3.51–4.16)

0.08

(0–0.17)

2.42

(2.26–2.58)

 Caucasian

3.73

(2.94–4.52)

7.51

(5.70–9.31)

17.29

(14.00–20.58)

6.12

(5.35–6.89)
k = 6; I2: 98.78 k = 16; I2: 99.75 k = 6; I2: 92.40 k = 29; I2: 99.75 k = 13; I2: 98.68 k = 14; I2: 99.28 k = 2; I2: 0 k = 29; I2: 99.11
Asian

1.60

(0.73–2.47)

1.45

(0.61–2.28)

1.08

(0.76–1.4)

1.39

(0.95–1.83)

 Asian

7.74

(0.97–14.52)

9.09

(4.99–13.20)

 -

7.38

(5.08–9.68)
k = 3; I: 98.18 k = 4; I2: 99.30 k = 1; I2: 0 k = 8; I2: 98.78 k = 2; I2: 97.67 k = 4; I2: 99.07 - k = 7; I2: 0
World

7.30

(5.12–9.47)

3.19

(2.91–3.47)

0.16

(0.05–0.27)

2.06

(1.92–2.19)

 World

3.93

(3.22–4.65)

7.69

(6.10–9.27)

17.29

(14.00–20.58)

6.13

(5.43–6.83)
k = 10; I2: 99.64 k = 20; I2: 99.71 k = 7; I2: 94.51 k = 37; I2: 99.70 k = 16; I2: 98.50 k = 18; I2: 99.26 k = 2; I2: 0 k = 36; I2: 97.70
C. During/after the H1N1 pandemic in vaccinated populations D. Before and during/after the H1N1 pandemic in unvaccinated populations
Europe

21.72

(15.16–8.29)

2.66

(1.71–3.61)

8.36

(0–23.65)

6.56

(5.38–7.74)

 Europe

8.66

(4.20–13.11)

11.15

(8.40–13.91)

9.26

(6.46–12.06)

9.26

(6.46–12.06)
k = 9; I2: 98.11 k = 8; I2: 94.05 k = 2; I2: 87.40 k = 19; I2: 97.4 k = 14; I2: 99.00 k = 16; I2: 98.31 k = 14; I2: 99.26 k = 14; I2: 99.26
North America - -

4.32

(0–11.12)

4.32

(0–11.12)

 North America - -

6.91

(5.08–8.74)

6.91

(5.08–8.74)
- - k = 1; I2: 0 k = 1; I2: 0 - - k = 3; I2: 90.44 k = 3; I2: 90.44
Asia

0.65

(0.50–0.80)

2.95

(2.63–3.28)

 -

1.80

(0–4.05)

 Asia

6.85

(6.33–7.38)

21.40

(0–9.32)

2.92

(2.66–3.19)

13.12

(3.33–22.91)
k = 1; I2: 0 k = 1; I2: 0 - k = 2; I2: 99.4 k = 1; I2: 0 k = 2; I2: 99.96 k = 1; I2: 0 k = 4; I2: 99.91
Caucasian

21.72

(15.16–8.29)

2.66

(1.71–3.61)

5.86

(0–12.97)

6.51

(5.34–7.68)

 Caucasian

8.66

(4.20–13.11)

11.15

(8.40–13.91)

8.84

(6.56–11.12)

8.84

(6.56–11.12)
k = 9; I2: 98.11 k = 8; I2: 94.05 k = 3; I2: 76.72 k = 20; I2: 97.20 k = 14; I2: 99.00 k = 16; I2: 98.31 k = 17; I2: 99.10 k = 17; I2: 99.10
Asian

0.65

(0.50–0.80)

2.95

(2.63–3.28)

 -

1.80

(0–4.05)

 Asian

6.85

(6.33–7.38)

21.40

(0–9.32)

2.92

(2.66–3.19)

13.12

(3.33–22.91)
k = 1; I2: 0 k = 1; I2: 0 - k = 2; I2: 99.4 k = 1; I2: 0 k = 2; I2: 99.96 k = 1; I2: 0 k = 4; I2: 99.91
World

16.76

(12.84–0.67)

2.97

(1.88–4.06)

5.86

(0–12.97)

4.22

(3.49–4.94)

 World

8.46

(4.89–12.03)

12.53

(7.95–17.12)

8.50

(6.41–10.59)

9.66

(7.01–12.31)
k = 10; I2: 98.23 k = 9; I2: 97.70 k = 3; I2: 76.72 k = 22; I2: 97.7 k = 15; I2: 98.98 k = 18; I2: 99.53 k = 18; I2: 99.27 k = 21; I2: 99.62